Moderna shares pop 7% after Cowen upgrades stock, saying it 'will be a leader' in RSV vaccines
Publishing timestamp: 2023-03-13 17:45:19
Summary
Moderna's shares jumped after TD Cowen upgraded the stock, citing the company's potential in the RSV vaccine market and its pipeline of other vaccine candidates for diseases like flu. Moderna's RSV vaccine performed well in clinical trials and was well tolerated by patients, and the company intends to publish full data set and share results during an upcoming medical conference. While GSK and Pfizer are still one step ahead of Moderna in the race to approve the world's first vaccine against respiratory syncytial virus, Cowen noted that Moderna believes regulatory support of its competitors' RSV candidates "should read-through" to its own.
Sentiment: POSITIVE
Keywords: markets, stock markets, moderna inc, health care industry, td holdings inc,